Home Cart Sign in  
Chemical Structure| 681159-27-3 Chemical Structure| 681159-27-3

Structure of CBR-5884
CAS No.: 681159-27-3

Chemical Structure| 681159-27-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CBR-5884 is a noncompetitive 3-phosphoglycerate dehydrogenase (PHGDH) inhibitor with IC50=33 μM).

Synonyms: CBR-5884

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of CBR-5884

CAS No. :681159-27-3
Formula : C14H12N2O4S2
M.W : 336.39
SMILES Code : O=C(C1=C(C)C(SC#N)=C(NC(C2=CC=CO2)=O)S1)OCC
Synonyms :
CBR-5884
MDL No. :MFCD04451442

Safety of CBR-5884

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Breast cancer cell lines (MDA-MB-468, MDA-MB-436, HCC70, Hs578T) Breast cancer cell lines (MDA-MB-468, MDA-MB-436, HCC70, Hs578T) To evaluate the effect of CBR-5884 on the proliferation of breast cancer cell lines with high serine synthesis activity, results showed that CBR-5884 inhibited proliferation by 35% to 60% at 30 μM. Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):1778-83.
Carney cells Carney cells To evaluate the acute toxicity of CBR-5884, results showed that CBR-5884 was not generally cytotoxic at concentrations up to 40 μM during the 3-h treatment period. Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):1778-83.
LNT-229 cells LNT-229 cells Under both serum and serum-free conditions, CBR-5884 significantly inhibited cell proliferation. Br J Cancer. 2020 Apr;122(9):1391-1398.
LN-308 cells LN-308 cells Under both serum and serum-free conditions, CBR-5884 significantly inhibited cell proliferation. Br J Cancer. 2020 Apr;122(9):1391-1398.
G55 cells G55 cells Measurement of intracellular serine, glycine, asparagine, and tyrosine levels showed that CBR-5884 significantly reduced serine and glycine levels. Br J Cancer. 2020 Apr;122(9):1391-1398.
Candida albicans SC5314 Candida albicans SC5314 Test the inhibitory effect of CBR-5884 on cell growth, results showed that CBR-5884 inhibited cell growth at 170 µM. mBio. 2024 May 8;15(5):e0063324.
IOSE-80 cells IOSE-80 cells Evaluate the effect of CBR-5884 on IOSE-80 cells, results showed minimal effect on IOSE-80 cells Discov Oncol. 2024 May 11;15(1):154.
MDA-MB-231 cells MDA-MB-231 cells Evaluate the effect of CBR-5884 on MDA-MB-231 cells, results showed minimal effect on MDA-MB-231 cells Discov Oncol. 2024 May 11;15(1):154.
ID8 cells ID8 cells Evaluate the inhibitory effect of CBR-5884 on ID8 cells, results showed CBR-5884 effectively downregulated serine biosynthesis Discov Oncol. 2024 May 11;15(1):154.
SKOV3 cells SKOV3 cells Evaluate the inhibitory effect of CBR-5884 on SKOV3 cells, results showed CBR-5884 effectively downregulated serine biosynthesis Discov Oncol. 2024 May 11;15(1):154.
Human MOLM13 cell line Human MOLM13 cell line To evaluate the effect of CBR5884 on leukemia cell proliferation, results showed that CBR5884 significantly inhibited the proliferation and clonogenic ability of leukemia cells. Blood Adv. 2020 Aug 11;4(15):3626-3638.
Murine MLL-ENL-transformed primary HSPCs Murine MLL-ENL-transformed primary HSPCs To evaluate the effect of CBR5884 on leukemia cell proliferation, results showed that CBR5884 significantly inhibited the proliferation and clonogenic ability of leukemia cells. Blood Adv. 2020 Aug 11;4(15):3626-3638.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude mice Xenograft tumor model established by subcutaneous injection of ID8 cells Intragastric administration 70 mg/kg Once daily for 12 consecutive days Evaluate the antitumor effect of CBR-5884 in vivo, results showed CBR-5884 significantly delayed tumor growth Discov Oncol. 2024 May 11;15(1):154.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.97mL

0.59mL

0.30mL

14.86mL

2.97mL

1.49mL

29.73mL

5.95mL

2.97mL

References

 

Historical Records

Categories